Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 1.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 786,312 shares of the company's stock after selling 11,425 shares during the period. Wellington Management Group LLP owned approximately 1.32% of Twist Bioscience worth $36,540,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at $34,000. Van ECK Associates Corp grew its position in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. US Bancorp DE increased its stake in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the period. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the third quarter worth about $95,000. Finally, KBC Group NV boosted its stake in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the period.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $62,131.65. Following the transaction, the senior vice president now directly owns 132,014 shares of the company's stock, valued at $6,514,890.90. The trade was a 0.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dennis Cho sold 806 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the sale, the insider now owns 112,221 shares of the company's stock, valued at approximately $5,538,106.35. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,796 shares of company stock valued at $1,077,383 over the last ninety days. Insiders own 3.01% of the company's stock.

Remove Ads

Analyst Ratings Changes

TWST has been the topic of several recent research reports. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. Finally, JPMorgan Chase & Co. increased their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $52.80.

Twist Bioscience Stock Up 6.1 %

Shares of NASDAQ:TWST traded up $2.22 on Friday, hitting $38.85. 1,136,088 shares of the company's stock were exchanged, compared to its average volume of 978,930. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a market capitalization of $2.32 billion, a PE ratio of -11.49 and a beta of 2.34. The firm's 50-day moving average is $41.83 and its 200 day moving average is $44.66.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.75) earnings per share. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.